BRPI0513257A - composição farmacêutica lìquida - Google Patents

composição farmacêutica lìquida

Info

Publication number
BRPI0513257A
BRPI0513257A BRPI0513257-6A BRPI0513257A BRPI0513257A BR PI0513257 A BRPI0513257 A BR PI0513257A BR PI0513257 A BRPI0513257 A BR PI0513257A BR PI0513257 A BRPI0513257 A BR PI0513257A
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
liquid pharmaceutical
preservatives
active substance
relates
Prior art date
Application number
BRPI0513257-6A
Other languages
English (en)
Inventor
Domenico Fanara
Jean Scouvart
Claire Poulain
Michel Deleers
Original Assignee
Ucb Farchim Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34925743&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0513257(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ucb Farchim Sa filed Critical Ucb Farchim Sa
Publication of BRPI0513257A publication Critical patent/BRPI0513257A/pt
Publication of BRPI0513257B1 publication Critical patent/BRPI0513257B1/pt
Publication of BRPI0513257C1 publication Critical patent/BRPI0513257C1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Otolaryngology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

COMPOSIçãO FARMACêUTICA LìQUIDA. A presente invenção refere-se a uma composição líquida contendo uma substância ativa pertencendo à família de piperazinas de benzidrila substituídas com quantidades reduzidas de conservantes.
BRPI0513257A 2004-07-14 2005-07-07 composição farmacêutica líquida de derivados de piperazina BRPI0513257C1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP04016519 2004-07-14
EP04016519.3 2004-07-14
PCT/EP2005/007340 WO2006005507A2 (en) 2004-07-14 2005-07-07 Pharmaceutical composition of piperazine derivatives

Publications (3)

Publication Number Publication Date
BRPI0513257A true BRPI0513257A (pt) 2008-04-29
BRPI0513257B1 BRPI0513257B1 (pt) 2018-05-29
BRPI0513257C1 BRPI0513257C1 (pt) 2021-05-25

Family

ID=34925743

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0513257A BRPI0513257C1 (pt) 2004-07-14 2005-07-07 composição farmacêutica líquida de derivados de piperazina

Country Status (25)

Country Link
US (1) US8633194B2 (pt)
EP (1) EP1768649B1 (pt)
JP (1) JP4902875B2 (pt)
KR (1) KR101185612B1 (pt)
CN (1) CN100508981C (pt)
AR (1) AR049846A1 (pt)
AT (1) ATE443512T1 (pt)
AU (1) AU2005261953B2 (pt)
BR (1) BRPI0513257C1 (pt)
CA (1) CA2573662A1 (pt)
CY (1) CY1109670T1 (pt)
DE (1) DE602005016802D1 (pt)
EA (1) EA012463B1 (pt)
ES (1) ES2332462T3 (pt)
IL (1) IL180010A0 (pt)
MX (1) MX2007000230A (pt)
MY (1) MY149403A (pt)
NO (1) NO337768B1 (pt)
NZ (1) NZ552182A (pt)
PE (1) PE20060484A1 (pt)
PL (1) PL1768649T3 (pt)
PT (1) PT1768649E (pt)
TW (1) TWI304339B (pt)
WO (1) WO2006005507A2 (pt)
ZA (1) ZA200700939B (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2408453B1 (en) 2009-03-17 2022-01-05 Nicox Ophthalmics, Inc. Ophthalmic formulations of cetirizine and methods of use
US8569273B2 (en) 2009-03-17 2013-10-29 Aciex Therapeutics, Inc. Ophthalmic formulations of cetirizine and methods of use
TWI503122B (zh) * 2012-02-15 2015-10-11 Taiho Pharmaceutical Co Ltd Oral administration of pharmaceutical compositions
KR102155836B1 (ko) 2013-02-22 2020-09-14 삼성전자주식회사 터치 스크린 상에서 객체 디스플레이를 제어하는 휴대 단말 및 방법
US11241426B2 (en) 2017-02-13 2022-02-08 Nitto Medic Co., Ltd. Aqueous composition for ophthalmic or nasal administration
CN113712907A (zh) * 2020-05-25 2021-11-30 南京帝昌医药科技有限公司 一种盐酸左西替利嗪滴眼液组合物及其制备方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4255358A (en) * 1978-03-13 1981-03-10 The Secretary Of State For Defence In Her Britannic Majesty's Government Of The United Kingdom Of Great Britain And Northern Ireland Process for the production of hexanitrostilbene
FI75816C (fi) 1981-02-06 1988-08-08 Ucb Sa Foerfarande foer framstaellning av terapeutiskt aktiv 2-/4-(difenylmetyl)-1-piperazinyl/-aettiksyror eller dess amid.
NZ215069A (en) * 1985-03-01 1988-06-30 Reckitt & Colmann Prod Ltd Pharmaceutical composition with histamine h 2 -receptor antagonist
US4728509A (en) * 1985-08-19 1988-03-01 Takeda Chemical Industries, Ltd. Aqueous liquid preparation
JP3278192B2 (ja) * 1992-04-03 2002-04-30 ロート製薬株式会社 徐放性液剤
TW401300B (en) 1992-12-25 2000-08-11 Senju Pharma Co Antiallergic composition for ophthalmic or nasal use
US5504113A (en) * 1994-03-02 1996-04-02 Allergan, Inc. Enhancement of benzalkonium chloride preservative activity in formulations containing an incompatible drug
CA2201134A1 (en) * 1994-10-10 1996-04-18 Alfred Sallmann Ophthalmic and aural compositions containing diclofenac potassium
TW536403B (en) * 1997-03-24 2003-06-11 Glaxo Group Ltd An ethanol and ethylenediaminetetraacetic acid free pharmaceutical composition comprising lamivudine and exhibiting antimicrobial preservative efficacy
US6432961B1 (en) * 1998-08-18 2002-08-13 Ucb S.A. Method for preventing the onset of asthma
AUPQ419099A0 (en) * 1999-11-23 1999-12-16 Ko, Thomas Sai Ying Novel compositions and methods
DE10007203A1 (de) * 2000-02-17 2001-08-23 Asta Medica Ag Neue Kombination nichtsedierender Antihistaminika mit Substanzen, die die Leukotrienwirkung beeinflussen, zur Behandlung der Rhinitis/Konjunktivitis
US6258814B1 (en) * 2000-10-13 2001-07-10 Schering Corporation Method of using cetirizine and pharmaceutical compositions containing the same for inducing sleep
UA80393C2 (uk) * 2000-12-07 2007-09-25 Алтана Фарма Аг Фармацевтична композиція, яка містить інгібітор фде 4, диспергований в матриці
AU2002221854A1 (en) 2000-12-15 2002-06-24 U C B, S.A. Use of cetirizine or efletirizine for preventing urticaria
US6869618B2 (en) * 2001-04-10 2005-03-22 Kiel Laboratories, Inc. Process for preparing tannate liquid and semi-solid dosage forms
CA2488202C (en) * 2002-06-12 2011-03-08 Chemocentryx, Inc. 1-aryl-4-substituted piperazine derivatives for use as ccr1 antagonists for the treatment of inflammation and immune disorders
AU2003251152A1 (en) 2002-07-03 2004-01-23 Shannon Biotechnology Ltd Pharmaceutical formulations for preparing drink products
EP1569650B1 (en) 2002-12-03 2008-05-28 Ucb Farchim S.A. Use of levocetirizine for the treatment of persistent allergic rhinitis
US20050255154A1 (en) 2004-05-11 2005-11-17 Lena Pereswetoff-Morath Method and composition for treating rhinitis
US20090137645A1 (en) * 2007-10-31 2009-05-28 Midlothian Laboratories, Llc Shelf-Stable Famotidine Granulates for Oral Suspensions

Also Published As

Publication number Publication date
BRPI0513257B1 (pt) 2018-05-29
EA200700067A1 (ru) 2007-08-31
CA2573662A1 (en) 2006-01-19
AU2005261953B2 (en) 2010-06-03
ATE443512T1 (de) 2009-10-15
NO337768B1 (no) 2016-06-20
EP1768649B1 (en) 2009-09-23
TWI304339B (en) 2008-12-21
US20070275974A1 (en) 2007-11-29
DE602005016802D1 (de) 2009-11-05
JP2008505949A (ja) 2008-02-28
AU2005261953A1 (en) 2006-01-19
BRPI0513257C1 (pt) 2021-05-25
PE20060484A1 (es) 2006-07-06
KR20070043841A (ko) 2007-04-25
CY1109670T1 (el) 2014-08-13
MY149403A (en) 2013-08-30
NZ552182A (en) 2010-07-30
HK1103958A1 (zh) 2008-01-04
CN1984641A (zh) 2007-06-20
EP1768649A2 (en) 2007-04-04
WO2006005507A8 (en) 2006-12-07
WO2006005507A3 (en) 2006-04-27
JP4902875B2 (ja) 2012-03-21
ES2332462T3 (es) 2010-02-05
US8633194B2 (en) 2014-01-21
PL1768649T3 (pl) 2010-02-26
IL180010A0 (en) 2007-05-15
CN100508981C (zh) 2009-07-08
NO20070832L (no) 2007-02-13
EA012463B1 (ru) 2009-10-30
KR101185612B1 (ko) 2012-09-24
ZA200700939B (en) 2008-08-27
AR049846A1 (es) 2006-09-06
WO2006005507A2 (en) 2006-01-19
PT1768649E (pt) 2009-11-13
MX2007000230A (es) 2007-03-30
TW200605892A (en) 2006-02-16

Similar Documents

Publication Publication Date Title
EA200901617A1 (ru) Борсодержащие молекулы небольшого размера
BRPI0520669A2 (pt) dosagem farmacêutica que reduz o efeito do alimento encontrado para administração de atorvastatina
FR14C0069I1 (fr) Composition pharmaceutique comprenant le lurasidone
BRPI0411528A (pt) uso de isomalte como prebiótico
DE60334773D1 (de) Formulierungen zur oralen verabreichung von wirkstoffen
CL2011000835A1 (es) Compuestos derivados de espiro-oxindol; moduladores de los canales de sodio; composicion farmaceutica que comprende a dicho compuesto; y uso en el tratamiento del dolor, depresion, enfermedades cardiovasculares, respiratorias, psiquiatricas, entre otras.
CL2012000469A1 (es) Composición farmacéutica que comprende un compuesto conjugado de insulina de absorcion lenta; un envase; una suspensión que comprende la composición y su método de preparación; su uso para el tratamiento o prevención de una patología asociado a deficiencia de insulina, como diabetes; un kit.
CL2008003116A1 (es) Compuestos heterocíclicos bicíclicos; composición farmacéutica que comprende a dichos compuestos; y su uso en el tratamiento o prevención de enfermedades tales como diabetes, obesidad, trastorno metabólico, enfermedad cardiovascular entre otras.
BR112015010102A2 (pt) compostos heterocíclicos substituídos por amida úteis como moduladores de respostas de il-12, il-23 e/ou ifnalfa
MX336741B (es) Composiciones farmaceuticas de moduladores de c-met.
BR122013025375B8 (pt) compostos orgânicos, seus métodos de preparo e uso, bem como composições farmacêuticas
SV2008003088A (es) Nueva forma cristalina vi de la agomelatina, su procedimiento de preparacion y las composiciones farmaceuticas que la contienen
CU20060037A7 (es) Forma cristalina gamma del clorhidrato de la ivabradina, su procedimiento de preparación y las composiciones farmacéuticas que las contienen
ES2426258T8 (es) Composiciones farmacéuticas que comprenden bacterias que reducen oxalato
UY29856A1 (es) Forma cristalina 8d del clorhidrato de la ivabradina, su procedimiento de preparación, y las composiciones farmaceuticas que la contienen
CR8824A (es) Derivados de 2-carbamida-4-feniltiazol, su preparacion y su aplicacion en terapeutica
ECSP099776A (es) Moduladores de la gamma secretasa
GEP20135959B (en) Aryl piperazine and their usage as alpha2c antagonists
BRPI0717369A2 (pt) Composto, medicamento, composição farmacêutica que o contém e uso do composto.
EA201170512A1 (ru) Композиция для перорального введения
NO20085317L (no) Imidazoazepinonforbindelser
CY1109670T1 (el) Φαρμακευτικη συνθεση παραγωγων πιπεραζινης
BRPI0620229A8 (pt) formulação
BRPI0815455B8 (pt) compostos derivados de n-fenilacetamida, composição farmacêutica, composição cosmética, uso cosmético de uma composição, e usos de um composto do mesmo
NO20082848L (no) Farmasoytisk formulering for behandling av osteoartritt inneholdende klodronsyre og hyaluronsyre

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 29/05/2018, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 29/05/2018, OBSERVADAS AS CONDICOES LEGAIS. (CO) REFERENTE A RPI 2473 DE 29/05/2018, QUANTO AO ENDERECO DA DEPOSITANTE.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 07/07/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF